SLC25A35

Across TCGA pan-cancer cohorts, SLC25A35 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC25A35 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC25A35 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC25A35 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where SLC25A35 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.315	0.626	.005	33	view →
CCRCC	OS	Tertile	IV	1.000	0.204	.036	7	view →
LUAD	OS	Tertile	III,IV	0.931	0.435	.027	6	view →
LSCC	DFS	Median	II,III,IV	1.000	0.419	.008	3	view →
GBM	OS	Tertile	All	0.885	0.721	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC25A35–PDAC (DFS)

Open the PDAC breakdown →